We are a boutique, women‑owned consultancy helping pharma, device, biotech, and medtech launch AI and ML-enabled digital health devices (SaMD), medical devices, and combination products. Core strengths: regulatory strategy, HF/UE, clinical/analytical validation, and quality. Input from patients, caregivers, advocacy groups, academia, and industry experts is paramount to developing health care innovations across the drug, device and medical software industries that advance care and improve outcomes. Patient Centricity begins with gathering input early in the development process from patients to compassionately understand their needs.
Product adoption depends on early and sustained patient engagement with thoughtful attention to individual preferences and diversity. Using various insight gathering techniques designed to collect key information regarding unmet needs, Innovenn connects patients with industry innovators, healthcare providers, and advocacy groups to inclusively and respectfully enable the best experience and outcomes.
Innovenn operates under a rigorous Quality Management System aligned with U.S. FDA and international regulatory standards, so that every project is developed with compliance and risk management in mind. Our expertise includes:
- FDA consulting and regulatory strategy
- Global regulatory affairs consulting
- Clinical validation and usability testing
- Risk-based development processes
This regulatory foundation helps our clients reduce risk, accelerate development timelines, and achieve successful product approvals.
With years of experience in drug and device development utilizing a structured risk-based lifecycle process, the Innovenn team will help manage a successful product development projects enabling regulatory approvals, product adoption and market success for patient-centric health innovations.
